报价延迟最少15分钟:2026/04/21 19:06 EDT
盘后时段
|
||||
|
9.47 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.47
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.18/-1.03
|
|
企业价值
887.28M
|
| 资产负债 |
|
每股账面净值
1.96
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
67.48M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases. |
